Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
To evaluate:
1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural
history of patients affected with HCV decompensated cirrhosis, after sustained
virological response. A controlled study.
2. safety and efficacy of antiviral therapy in this population by using a statistically
significally number of patients as controls.